VEGF-2: Phase I/II

In a U.S. Phase I/II trial in 30 patients with Class III or IV angina, VEGF-2 given by intra-cardiac injection through a chest incision gave a decrease in angina severity and an increase in exercise tolerance. After 20 months, 83% of patients had marginal angina (Class I or II) and 17% reported a decrease in anginal pain. ...